U.S. Markets closed

Midatech Pharma plc (MTPH.L)

LSE - LSE Delayed Price. Currency in GBp
Add to watchlist
37.00-1.00 (-2.63%)
At close: 5:38PM BST
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close38.00
Open38.00
Bid36.00 x 0
Ask38.00 x 0
Day's Range35.25 - 40.50
52 Week Range18.10 - 87.00
Volume2,880,354
Avg. Volume91,977
Market Cap23.451M
Beta (5Y Monthly)1.75
PE Ratio (TTM)N/A
EPS (TTM)-94.50
Earnings DateMay 17, 2021 - May 21, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est67.00
  • TipRanks

    Thursday’s Pre-Market: Here’s What You Need to Know Before the Market Opens

    U.S. stock futures dipped on Thursday as investors await data related to the pace of recovery in the labor market. The weekly unemployment claims report and the Philadelphia Fed business outlook report for June will be released today. S&P, Dow, and Nasdaq futures were in red at the time of writing, with 0.3%, 0.2%, and 0.4% lower trading, respectively. Commercial Metals Company (CMC), Jabil Circuit (JBL), and Kroger Company (KR) are expected to report earnings before the market opens, while Dyna

  • Midatech Pharma Stock Jumps After Breakthrough Data On Encapsulation Of Biologic Using Q-Sphera
    Benzinga

    Midatech Pharma Stock Jumps After Breakthrough Data On Encapsulation Of Biologic Using Q-Sphera

    Midatech Pharma PLC (NASDAQ: MTP) has announced a breakthrough in vitro data utilizing Q-Sphera technology and progress across multiple other programs. The technology showed potential to formulate proteins into long-acting injectable products. Q-Sphera can encapsulate drugs in polymer-based bioresorbable microspheres, which may be injected to form depots in the body that release drugs over predictable, sustained periods from one week to several months. Pipeline Update: Monoclonal antibody (mAb)

  • TheStreet.com

    Premarket Movers Thursday: CureVac, Midatech Pharma, Honest Co.

    Stock futures were lower on Thursday after the Federal Reserve left interest rates unchanged but signaled it expected to increase rates earlier than expected. CureVac tumbled after the biopharma said that a late-stage study of its COVID-19 vaccine candidate "did not meet prespecified statistical success criteria." CureVac said that the second interim analysis of its Phase 2b/3 study in 40,000 subjects demonstrated interim vaccine efficacy of 47% against COVID-19 of any severity.